Gene therapy progress and prospects: Recombinant adeno-associated virus (rAAV) vectors

Gene Therapy

Volumn 11, Issue 10, 2004, Pages 805-810

  Flotte, T R ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; BLOOD CLOTTING FACTOR 9; DNA; PARVOVIRUS VECTOR; PROTEASOME;

CLINICAL TRIAL; CYSTIC FIBROSIS; DNA MODIFICATION; DRUG EFFICACY; ENHANCER REGION; GENE THERAPY; GENE TRANSFER; GENETIC CODE; GENETIC TRANSDUCTION; HEMOPHILIA B; HUMAN; NONHUMAN; POLYADENYLATION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SEROTYPE; TRANSCRIPTION INITIATION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS RECOMBINANT;

DEPENDOVIRUS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS;

ADENO-ASSOCIATED VIRUS; PARVOVIRUS;

EID: 2642539509     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302233     Document Type: Review

References (45)

1. Haberman RP, McCown TJ, Samulski RJ. Novel transcriptional regulatory signals in the adeno-associated virus terminal repeat A/D junction element. J Virol 2000; 74: 8732-8739.
2. Gao G et al. Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc Natl Acad Sci USA 2003; 100: 6081-6086.
3. Xie Q et al. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci USA 2002; 99: 10405-10410.
4. Opie SR et al. Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J Virol 2003; 77: 6995-7006.
5. Wu P et al. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism [in process citation]. J Virol 2000; 74: 8635-8647.
6. Zabner J et al. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J Virol 2000; 74: 3852-3858.
7. Kaludov N et al. Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol 2001; 75: 6884-6893.
8. Grimm D et al. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood 2003; 102: 2412-2419.
9. Chao H et al. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther 2000; 2: 619-623.
10. Loiler SA et al. Targeting recombinant adeno-associated virus vectors to enhance gene transfer to pancreatic islets and liver. Gene Therapy 2003; 10: 1551-1558.
11. Buning H et al. Receptor targeting of adeno-associated virus vectors. Gene Therapy 2003; 10: 1142-1151.
12. Rabinowitz JE et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 2002; 76: 791-801.
13. Davidson BL et al. Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci USA 2000; 97: 3428-3432.
14. Duan D et al. Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J Clin Invest 2000; 105: 1573-1587.
15. Hansen J et al. Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts. J Virol 2000; 74: 992-996.
16. Srivastava A. Obstacles to human hematopoietic stem cell transduction by recombinant adeno-associated virus 2 vectors. J Cell Biochem Suppl 2002; 38: 39-45.
17. Yan Z et al. Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors. J Virol 2002; 76: 2043-2053.
18. Bartlett JS, Wilcher R, Samulski RJ. Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J Virol 2000; 74: 2777-2785.
19. Qing K et al. Adeno-associated virus type 2-mediated gene transfer: role of cellular FKBP52 protein in transgene expression. J Virol 2001; 75: 8968-8976.
20. McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transcluction independently of DNA synthesis. Gene Therapy 2001; 8: 1248-1254.
21. Song S, Laipis PJ, Berns KI, Flotte TR. Effect of DNA-dependent protein kinase on the molecular fate of the rAAV2 genome in skeletal muscle. Proc Natl Acad Sci USA 2001; 98: 4084-4088.
22. Yan Z, Ritchie TC, Duan D, Engelhardt JF. Recombinant AAV-mediated gene delivery using dual vector heterodimerization. Methods Enzymol 2002; 346: 334-357.
23. Sun L, Li J, Xiao X. Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. Nat Med 2000; 6: 599-602.
24. Reich SJ et al. Efficient trans-splicing in the retina expands the utility of adeno-associated virus as a vector for gene therapy. Hum Gene Ther 2003; 14: 37-44.
25. Zolotukhin S et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 2002; 28: 158-167.
26. Potter M et al. Streamlined large-scale production of recombinant adeno-associated virus (rAAV) vectors. Methods Enzymol 2002; 346: 413-430.
27. Gao G et al. Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo [in process citation]. Hum Gene Ther 2000; 11: 2079-2091.
28. Beck SE et al. Deposition and expression of aerosolized rAAV vectors in the lungs of Rhesus macaques. Mol Ther 2002; 6: 546-554.
29. Acland GM et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 2001; 28: 92-95.
30. Owen Rt et al. Gene therapy for pyruvate dehydrogenase E1alpha deficiency using recombinant adeno-associated virus 2 (rAAV2) vectors. Mol Ther 2002; 6: 394-399.
31. Miao CH et al. Nonrandom transduction of recombinant adeno-associated virus vectors in mouse hepatocytes in vivo: cell cycling does not influence hepatocyte transduction. J Virol 2000; 74: 3793-3803.
32. Nakai H et al. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol 2001; 75: 6969-6976.
33. Nakai H et al. A limited number of transducible hepatocytes restricts a wide-range linear vector dose response in recombinant adeno-associated virus-mediated liver transduction. J Virol 2002; 76: 11343-11349.
34. Song S et al. Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors. Gene Therapy 2001; 8: 1299-1306.
35. Xu L et al. CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. Hum Gene Ther 2001; 12: 563-573.
36. Flotte TR et al. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Hum Gene Ther 2003; 14: 1079-1088.
37. Wagner JA et al. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum Gene Ther 2002; 13: 1349-1359.
38. Aitken ML et al. A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Hum Gene Ther 2001; 12: 1907-1916.
39. Kay MA et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector [see comments]. Nat Genet 2000; 24: 257-261.
40. Manno CS et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003; 101: 2963-2972.
41. Virella-Lowell I et al. Inhibition of recombinant adeno-associated virus (rAAV) transduction by bronchial secretions from cystic fibrosis patients. Gene Therapy 2000; 7: 1783-1789.
42. Rooney CP et al. Bronchoalveolar fluid is not a major hindrance to virus-mediated gene therapy in cystic fibrosis. J Virol 2002; 76: 10437-10443.
43. Mah C et al. Improved method of recombinant AAV2 delivery for systemic targeted gene therapy. Mol Ther 2002; 6: 106-112.
44. Halbert CL et al. Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J Virol 2000; 74: 1524-1532.
45. Rideout III WM et al. Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy Cell 2002; 109: 17-27.